← Back to Investors

venBio Partners

venBio Partners is a life sciences venture capital firm founded by veteran biotechnology executives and scientists. The firm combines deep scientific expertise with operational experience to build transformative biotechnology companies across therapeutics, diagnostics, and tools.

Location
San Francisco, California, USA
Founded
2014
AUM
$1.5B+
Investment Range
$5M - $75M
Focus
biotech-focused
Fund Stages
seed, series-a, series-b, series-c, growth

Investment Thesis

venBio invests in innovative biotechnology companies with differentiated science and experienced teams. They focus on companies addressing significant unmet medical needs with novel therapeutic approaches. The firm brings hands-on expertise from decades of experience building and leading biotechnology companies.

Team

Partners / Managing Directors

  • Corey Goodman, PhD - Founder & Managing Partner (former UC Berkeley professor, Renovis founder)
  • Robert Adelman, MD - Managing Partner (former Alteon Pharma CEO)
  • Aaron Royston, MD - General Partner
  • Jenny Barnett - General Partner

Other Key Team Members

  • Scientific Advisory Network with deep expertise across therapeutic areas

Focus Areas

  • Oncology
  • Immunology
  • Neuroscience
  • Metabolic Diseases
  • Rare Diseases
  • Gene & Cell Therapy
  • Drug Discovery Platforms

Notable Portfolio Companies

  • Turning Point Therapeutics - Precision oncology (IPO 2019, acquired by BMS)
  • ChemoCentryx - Inflammatory diseases (acquired by Amgen)
  • Enliven Therapeutics - Kinase inhibitors (IPO 2022)
  • Nurix Therapeutics - Protein degradation (IPO 2020)
  • Poseida Therapeutics - Cell therapies (IPO 2020)

Notable Exits

  • Turning Point Therapeutics - IPO (2019), then Acquired (2022, acquired by BMS for $4.1B)
  • ChemoCentryx - Acquired (2022, acquired by Amgen for $3.7B)
  • Enliven Therapeutics - IPO (2022, NASDAQ: ELVN)
  • Nurix Therapeutics - IPO (2020, NASDAQ: NRIX)
  • Poseida Therapeutics - IPO (2020, NASDAQ: PSTX)

Sources